Home
Sign In
About
Curriculum
Activity Information
Target Audience
Learning Objectives
Technical Requirements
The Curriculum in Iron Metabolism & Related Disorders is supported by an educational grant from
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Course materials have been developed for use outside of the United States.
|
 |
|
|
|
|
|
End-Organ Damage Resulting from Accumulation of Iron in Cells
Provides clinicians with a comprehensive overview of iron metabolism and the steps leading to pathophysiologic conditions and resultant iron overload. Dr. Pierre Brissot of University Hospital Pontchaillou in Rennes, France provides clinical insights into iron overload, chronic disease states associated with iron overload, and end-organ damage due to iron overload causing morbidity and mortality.
|
|
Faculty
|
|
|
Pierre Brissot, MD
Professor of Medicine
Liver Disease Department
University Hospital Pontchaillou
Rennes, France
|
|
|
Target Audience
This activity is designed for haematologists, medical oncologists, haematology-oncology specialists, and other healthcare professionals involved in the screening, evaluation, treatment, and management of adults and children with iron overload, resulting from the spectrum of chronic iron overload diseases
|
Learning Objectives
After participating in this activity, participants should be better able to:
- Assess the molecular physiology of iron metabolism and the factors contributing to its pathophysiology and resultant iron overload, based on an understanding of hepcidin, ferroportin, transferrin, NTBI, LPI, transfusional iron overload, and genetic iron overload.
- Identify the spectrum of disease states associated with iron overload, both primary and secondary, and the clinical sequelae resulting from iron overload on the main visceral targets of iron excess (hepatic, cardiac, endocrine organs, skeletal system) as well as morbidity and mortality.
|
Disclosure Information
Pierre Brissot, MD, has received grant/research support from and is on the speakers bureau of Novartis Pharmaceuticals Corporation. Prof. Brissot has disclosed that he will not reference any unlabeled/unapproved uses of drugs or devices.
|
|
|
|
|
|
|
